PDK2 is upregulated in paclitaxel- or cisplatin resistant lung cancer cells compared to the parental cells and is associated with poor prognosis in patients with lung cancer (Sun et al., 2017; Hu et al., 2019). Here, PDK2 is linked to lung carcinoma.